在图雷特综合征中使用VMAT2抑制剂的现实世界经验
Karim Makhoul1, Joseph Jankovic2
1Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 7200 Cambridge, Suite 9A, Houston, TX, 77030-4202, USA.
膀单胺转运体2 (VMAT2) 抑制剂有效治疗带有轻微副作用的图雷特综合征,如抑郁症. 然而,由于缺乏FDA对这些VMAT2抑制剂的批准,美国的可访问性有限.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 图雷特综合征 (TS) 是一种神经疾病,其特点是运动和声乐的.
- 膀单胺转运体2 (VMAT2) 抑制剂用于非标签性滴答管理.
研究的目的:
- 审查对图雷特综合征使用VMAT2抑制剂 (四特拉贝纳,二特拉贝纳,瓦尔贝纳) 的实际经验.
- 评估这些药物的治疗益处,副作用概况和可获得性.
主要方法:
- 在4年内对164名接受VMAT2抑制剂治疗的患者进行了回顾性图表审查和电话调查.
- 评估治疗反应使用利克尔特尺度,比较治疗前和治疗期间的症状严重程度.
主要成果:
- VMAT2 抑制剂在降低的严重性方面表现出有效性.
- 报告的主要副作用是轻度抑郁;没有观察到自杀倾向.
- 收集了对特拉贝纳,杜特拉贝纳和瓦尔贝纳治疗持续时间和剂量的数据.
结论:
- VMAT2 抑制剂是对图雷特综合征的安全有效治疗选择.
- 在美国,有限的可访问性是一个重要的障碍,部分原因是缺乏FDA批准.
更多相关视频
11:06Bilateral Assessment of the Corticospinal Pathways of the Ankle Muscles Using Navigated Transcranial Magnetic Stimulation
Published on: February 19, 2019
08:55Online Transcranial Magnetic Stimulation Protocol for Measuring Cortical Physiology Associated with Response Inhibition
Published on: February 8, 2018
相关概念视频
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Drugs Acting on Autonomic Ganglia: Blockers
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
